Dr. Philippe Guédat has over 20 years of experience in drug discovery at industrial level. Philippe held positions of responsibility in the “business units” of which he was in charge. His expertise ranges from the discovery of chemical molecules with the implementation of high-throughput screening platforms to preclinical development of drug candidates. Medicinal chemist by training, he optimized a large number of chemical series in a variety of therapeutic areas and filed more than 20 patent families of molecules. He is also a consultant for several biopharmaceutical companies, “reviewer” for scientific journals and author of 18 scientific publications.
Philippe has a Master in medicinal chemistry and pharmacology, a Master of supramolecular organic chemistry and a PhD degree in medicinal chemistry and pharmacology from the University Louis Pasteur in Strasbourg. Philippe began his career at the University of Cambridge and at SmithKline Beecham (GSK) in England before joining Merck-Serono. He then joined Hybrigenics as Director of Chemistry where he set up the drug discovery business dedicated to ubiquitin specific proteases. He also developed the protein-protein interaction screening platform at Hybrigenics. Until early 2013, he headed the Drug Discovery department at Vivalis, France (today Valneva). When Vivalis shut down its small molecule department for strategic reasons, he founded InFlectis BioScience allowing it to showcase its scientific and managerial skills gained in the field. Philippe is President and Chief Executive Officer of the company InFlectis BioScience since inception.